Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker

About one to two million women in Taiwan suffers from overactive bladder (OAB). The most commonly used anti-muscarinic drugs have a high rate of side effects. While beta-3 adrenoceptor agonist, Mirabegron, has far fewer side effects, there are no consensus on whether it can be used as first-line treatment. The investigator's preliminary study showed that the concentration of beta-3 adrenoceptor in the urine of OAB patients is higher than that in the normal control group, so comparing urinary beta-3 adrenoceptor concentration of OAB patients before and after treatment may be used as a biomarker of therapeutic effectiveness. The results of this study will be of great help in understanding the effectiveness of Mirabegron and formulating OAB treatment plans.

Inclusion Criteria:

• Diagnosis compatible with 2002 ICS for overactive bladder syndrome
• Symptoms persisted for more than 3 months
• Completed pre-treatment urodynamic study
• Has plans for treatment with Mirabegron or Solifenacin due to clinical symptoms
• Patient is willing to cooperate with study including follow up and complete questionnaire surveys

Exclusion Criteria:

• Has stress urinary incontinence
• Pelvic organ prolapse
• Interstitial cystitis
• Constipation
• Gastroesophageal reflux disease
• Prior failed medical treatment for overactive bladder syndrome
• Uncontrolled hypertension
• Glaucoma
• Currently pregnant
• Using other medications for overactive bladder syndrome